AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01717326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
Study NCT03310749 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
Study NCT04366037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine training
Description: Training will be defined by each club coach
Study NCT04366037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine training + proprioceptive exercise in warm-up
Description: Training will be defined by each club coach, adding four proprioceptive exercises in warm-up:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds
Study NCT04366037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine training + proprioceptive exercise in cool-down
Description: Training will be defined by each club coach, adding four proprioceptive exercises in cool-down:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds
Study NCT03156478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention group
Description: Intervention with digital application for lifestyle changes
Study NCT03156478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined digital and face-to-face lifestyle intervention group
Description: Intervention with digital application and group meetings for lifestyle changes
Study NCT04620083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Learning Program for Old People with Dementia
Description: The program included modalities for reality orientation, daily living skills training, reminiscence therapy, multisensory stimulation, fall prevention program, mindfulness activities, Meridian exercise, brain health program (Four Arts of the Chinese Scholar which referred to zither, go, calligraphy and painting) and health education. It was also agreed that case managers, caregivers, and participants were free to choose these treatments or could be assigned to a treatment regime on a 'mix and match' basis to suit their personality traits for improving their abilities to meet their own needs. This program was developed by the team using Delphi technique.
Study NCT02719132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin, 10 mg
Study NCT02719132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin, 10 mg
Study NCT02719132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, up to 2500 mg
Study NCT02719132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin, up to 2500 mg
Study NCT00704028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: 15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
Study NCT00704028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Dextran
Description: As determined by the investigator to a maximum cumulative dose of 2,250 mg.
Study NCT03393156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based metacognitive therapy
Description: Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
Study NCT03322215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 75-125 mg capsule orally once daily for 21 consecutive Days followed by 7 Days of treatment.
Study NCT03322215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscularly Days 1 and 15 of cycle 1, and then on Day 1 of each subsequent 28-days cycle.
Study NCT02422524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
Study NCT00626561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV twice weekly on days 1 and 15.
Study NCT03322215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
Study NCT01340092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family Navigator
Description: Families in the intervention group will receive approximately six sessions with a Family Navigator. The Family Navigator will:~1. Help family identify key issues they need to address to get their child autism-specific services~2. Help family address barriers to obtaining these services and strategize approaches to overcome them.
Study NCT03483675 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunosuppressive Therapy
Description: Discontinued IST
Study NCT03483675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Therapy
Description: Continued IST
Study NCT00626561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 60 mg/m\^2 IV weekly on days 1, 8, 15, and 22.
Study NCT02308124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Study NCT02308124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Study NCT02308124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine + pyridostigmine
Study NCT03483675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04931121 — intervention group
Intervention type: DRUG
Intervention: Viscosupplements
Description: Synovial fluid is collected as part of a conventional injection of viscosupplement
Study NCT03483675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT01787175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Medication Manager
Description: A theory based electronic health record. Half of the provider participants were assigned the IMM to use. The other half were assigned the VA's CPRS EHR to use for the simulation. Providers were randomly assigned to a EHR to use.
Study NCT00799578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine
Description: Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
Study NCT03088761 — intervention group
Intervention type: DEVICE
Intervention: cuffed tracheal tube
Description: the changes in cuff pressure will be determined using a cuff manometer
Study NCT01663415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: oral
Study NCT00896558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322/placebo
Description: GSK1322322/placebo escalating doses from 500mg to 1500mg
Study NCT00896558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322/placebo and midazolam
Description: GSK1322322/placebo and 5mg midazolam
Study NCT01301495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANAROSTENT TM covered Esophageal Stent
Description: HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
Study NCT01139736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks
Study NCT01886807 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TrueView PCD Video Laryngoscope
Study NCT01886807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueView PCD Video Laryngoscope
Study NCT01978028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferric carboxymaltose
Study NCT01978028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01625143 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02124863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary Percussive Ventilation
Description: 20 min IPV freq 300/min, p 10cmH2O
Study NCT03089203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-PSMA-TGFβRDN cells
Description: autologous CAR T cells
Study NCT03089203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2/day given over 3 days
Study NCT03089203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day given over 3 days
Study NCT03454984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: 30/m2/day SubCutaneous for 5 days (Cycle = 28 days). total of 10 cycles
Study NCT03803280 — intervention group
Intervention type: PROCEDURE
Intervention: ERAS program
Description: ERAS pathway according to the Spanish Via RICA
Study NCT00748215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium aluminosilicate anti-diarrheal
Description: Given orally
Study NCT00748215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01717326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Elbasvir
Description: Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
Study NCT01717326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
Study NCT02716207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyberKnife
Description: Radiation Therapy
Study NCT04629235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wonder around
Description: wonder around after 8 hours of bedrest
Study NCT04629235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: bedrest
Description: 24 hours of bedrest
Study NCT03871803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Controlled withdrawal of beta-blockers
Description: Controlled withdrawal of previos doses of beta-blockers after diagnosis of chronotropic incompetence
Study NCT03871803 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Testing
Description: Cardiopulmonary Exercise Testing to evaluate the chronotropic incompetence and the primary endpoint (functional capacity)
Study NCT06301932 — intervention group
Intervention type: PROCEDURE
Intervention: Open liver resection
Description: The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
Study NCT00232856 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: drug-eluting stent
Description: PCI
Study NCT04831177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser in situ keratomileusis
Description: Laser in situ keratomileusis LASIK is a procedure used to correct different types of ametropia through a creation of corneal flap whether with femtosecond laser or mechanically with a microkeratome followed by application of excimer laser to correct different refractive errors including Myopia, Hyperopia and Astigmatism.
Study NCT01401608 — intervention group
Intervention type: DEVICE
Intervention: RF Ablation
Description: Ablation of arrhythmogenic ventricular tissue
Study NCT01620944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Capsule, oral, 300 mg, Once daily (QD), 96 weeks
Study NCT01620944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Capsule, oral, 300 mg, Once daily (QD), 96 weeks
Study NCT01620944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Tablets, oral, 100 mg, QD, 96 Weeks
Study NCT01620944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Tablets, oral, 100 mg, QD, 96 Weeks
Study NCT03322644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT intervention
Description: The Internet-delivered Pancreatitis Pain Course consists of 5 lessons: 1) introduction, education, and symptom identification, 2) thought monitoring and challenging, 3) controlled breathing and pleasant activity scheduling, 4) activity pacing, and 5) relapse prevention and goal setting. Participants aim to complete one online lesson weekly for 5 weeks, and have up to 2 months to complete the course. Each lesson has a homework assignment to encourage participants to practice and apply skills. A coach who is part of the Seattle Children's Research Institute study team will make weekly contact with participants in the intervention arm through telephone or secure e-mail, for a period of between 10-15 minutes to encourage participants to work through the Course and apply the skills.
Study NCT03376334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Motor Imagery
Study NCT03783325 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: UV Counseling
Description: This is a sub-study that involves a behavioral intervention. Participants will wear a UV dosimetry for 3 weeks, return the device and receive feedback. After the feedback, they will re-wear the device for an additional 3 weeks.
Study NCT03783325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UV Photo
Description: Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
Study NCT03783325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological Sample
Description: Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
Study NCT01739049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: liraglutide
Study NCT01191359 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: oral immunotherapy
Description: orally applied specific immunotherapy
Study NCT01739049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise
Description: diet and exercise
Study NCT01739049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: diet and exercise
Study NCT06753461 — intervention group
Intervention type: PROCEDURE
Intervention: intrahepatic blood flow occlusion
Description: The specified blood vessel is temporarily clamped to achieve the intended blockage of blood flow.
Study NCT01620944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Tablet, oral, 300 mg, QD, 96 Weeks
Study NCT01620944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine
Description: Tablets, oral, 300/200 mg, QD, 48 Weeks
Study NCT03852095 — intervention group
Intervention type: OTHER
Intervention: minor trauma
Description: following the management of the patient's fracture in the emergency department, the patients / parents are recalled 2 months (J60) after the visit to the emergency room, and are interviewed by following the pre-established interrogation form, which checks the good agreement of the patient. treatment performed with the given sheet and recommendations, and assesses the satisfaction.
Study NCT04445428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oral polio vaccine + information
Description: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
Study NCT06758167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XingpiJieyu formula
Description: XingpiJieyu formula is a traditional Chinese medicine. It pays attention to the regulation of qi and blood. Previous studies have shown that its clinical effect of treating mild and moderate depression is significant, for example, it can effectively improve depressive mood and somatic symptoms, and increase peripheral blood ATP levels in patients with depression.
Study NCT06758167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, no therapeutic effect.
Study NCT06758167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: A commonly used drug in MDD treatment.
Study NCT06758167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: A commonly used drug in MDD treatment.
Study NCT04560998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
Study NCT04560998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo (semaglutide) is administered s.c. once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
Study NCT00980460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00980460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Given IV
Study NCT00980460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00980460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT03001453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: 266mg liposomal bupivacaine
Study NCT03001453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine with epinephrine
Description: 0.25% bupivacaine with epinephrine
Study NCT04445428 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information
Description: Advice regarding how to protect oneself from COVID-19
Study NCT04445428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Advice regarding how to protect oneself from COVID-19
Study NCT04751149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of Urinary Catheter
Description: Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
Study NCT00032643 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DITPA
Study NCT01561352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.
Study NCT02220244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003 100mg capsule
Study NCT02220244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MD1003 100mg capsule
Study NCT03001453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Normal saline
Study NCT00390208 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab, dexamethasone and verteporfin
Description: One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.
Study NCT04611451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classic lumbar home exercise
Description: classic lumbar home exercise
Study NCT04611451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classic lumbar home exercise
Description: classic lumbar home exercise